Introduction
============

Benign prostatic hyperplasia (BPH) is the most common benign neoplasm in US males. Seventy-five percent of men in their seventh decade of life are affected ([@b104]). In 2000, approximately 8 million office visits were accounted for by a primary or secondary diagnosis of BPH ([@b104]). The number of office visits for BPH has recently increased, while the number of surgical interventions has decreased. This shift reflects the increased selection and availability of effective pharmacologic therapies ([@b104]).

BPH: Assessing quality of life
==============================

Validated symptom scoring questionnaires
----------------------------------------

Lower urinary tract symptoms (LUTS) can be related to BPH, and the degree of symptom severity dictates the impact on quality of life (QoL). Consistent and reliable evaluation of patient symptoms is necessary to quantify symptoms and determine treatment efficacy. To achieve this, various validated symptom scoring questionnaires have been designed and tested for consistency and reliability. These symptom scores are useful for both clinical and research assessments of medication efficacy.

Clinical research, some of which utilizes validated questionnaires, is the foundation for evidence-based medicine. The type of trial design contributes to the quality of the data it yields ([@b78]). Listed from most reliable to least reliable, systematic reviews and meta-analyses of randomized controlled trials (RCTs), nonrandomized controlled trials, case reports, clinical examples, and consensus meetings, are the different types of available evidence ([@b68]). Although evidence in the published literature has differing levels of importance, it can all play a role in patient management ([@b96]).

The most widely used and extensively validated symptom score assessment is the American Urological Association Symptom Index (AUASI) ([@b8]; [@b64]). The AUASI is composed of seven questions regarding incomplete emptying, frequency, intermittency, urgency, weakness of the urinary stream, straining, and nocturia. The test-retest correlation for this questionnaire is 0.92 ([@b8]).

Various questionnaires have been developed to quantitatively assess symptoms and QoL issues in BPH. Examples of validated questionnaires include: the Maine Medical Assessment Program score ([@b38]), the Boyarsky score ([@b15]), the Madsen-Iversen Score ([@b67]), International Prostate Symptom Score (IPSS) (AUASI plus one question regarding QoL) ([@b26]) and the Danish Prostatic Symptom Score ([@b45]; [@b72]).

BPH: Natural history
====================

Defining the natural history of BPH improves management and risk stratification. Community-based longitudinal studies and placebo arms of clinical trials have been used to define the natural history of BPH. Both study types have inherent limitations; however, the latter generally provides less reliable data than a community-based longitudinal study ([@b35]; [@b86]).

Surrogate endpoints of clinical progression are used to define natural history. Urinary symptom score, prostate volume, urinary flow rate, episodes of acute urinary retention (AUR), prostate-specific antigen (PSA), post-void residual (PVR), and surgery have been utilized as surrogate endpoints of disease progression.

American Urological Association Symptom Index
---------------------------------------------

The Olmsted County trial is a community-based, prospective cohort study initiated to define the natural history of BPH. The study included 2115 randomly selected men between the ages of 40 to 79 years from Olmsted County, Minnesota ([@b94]). An age-associated worsening AUASI and bother score was noted at baseline and last follow-up. The greatest increase in symptom and bother scores occurred during the seventh decade of life. Specifically, nocturia and weak stream demonstrated the strongest association with aging. All seven AUASI symptoms demonstrated significant progression with time and age. Symptoms related to voiding or obstruction were the most common, while symptoms related to storage, irritation, or social embarrassment were the most bothersome. These findings suggest a slowly progressive natural history of BPH with acceleration in symptom severity among individuals in their seventh decade of life ([@b94]).

Prostate volume
---------------

The Olmsted County study also investigated prostate growth. Prostate volume was determined in 631 men by transrectal ultrasound. After seven years of follow-up, the annual change in volume was 1.6% across all age groups ([@b82]). Increasing growth rate was observed with increasing age and baseline prostate volume ([@b82]).

[@b13] reported the prevalence and growth rate of BPH with age by collecting data from 10 studies accounting for over 1000 cadaveric prostate samples. Men between the ages of 21 and 30 had an average prostate mass of 20g. In the absence of BPH, the prostate remained at this size. Prostates that develop BPH had a greater growth velocity in men between 31 and 50 years of age (doubling time 4.5 years), while men between the ages of 51 and 70 had a slower doubling time of 10 years, and men over 70 had doubling times greater than 100 years. Eight percent of men in their fifth decade of life were shown to have pathological BPH, while half of men in their sixth decade of life were shown to have the condition.

Peak urinary flow rate
----------------------

Peak urinary flow rate is another surrogate endpoint for clinical progression of BPH. The Olmsted County trial data demonstrated an annual median peak urinary flow rate slope of −2.1% ([@b85]). Rapid decline in peak urinary flow rate was associated with decreasing baseline flow rate, and increasing baseline age, prostate volume and symptom severity (p = 0.001).

Acute urinary retention
-----------------------

The Olmsted County trial data demonstrated increasing incidence of AUR associated with age and severity of symptoms. Decreased peak urinary flow rates indicated a four-fold increased risk of AUR, and men with prostates greater than 30 cc experienced a three-fold increase in risk. Risk of AUR, within a five-year period, was 1.6% and 10% for men aged 40--49 and 70--79 years, respectively ([@b49]). AUR is a painful episode with proven negative impact on QoL. Risk factors for AUR and proven efficacy in minimizing this risk are important patient and pharmaceutical factors.

Prostate-specific antigen
-------------------------

Increasing PSA ([@b89]; [@b105]) is a risk factor for prostate enlargement and may be predictive of risk of developing BPH ([@b89]; [@b35]). PSA alone (sensitivity 75%, specificity 64%) has been shown to be comparable with both expanded models (PSA, urinary frequency and hesitancy, flow rate parameters, and symptom problem index, sensitivity 72%, specificity 67%) and a scoring algorithm as a predictor of disease progression defined by AUR episode ([@b89]). Although both PSA and prostate volume can be assessed for risk of progression, PSA is more reliable and cheaper than assessing prostate volume with digital rectal exam, transrectal ultrasound, or magnetic resonance imaging ([@b35]).

Post-void residual
------------------

The Olmsted County Study data has also been used to describe the natural history of PVR and voided volume in 529 community dwelling men between the ages of 40 to 79 ([@b93]). Median annual change in PVR was 2.2% and voided volume was −2.1%. These data suggest gradually increasing PVR and decreasing voided volume; however a clear association has not yet been established between PVR, voided volume, and lower urinary tract symptoms (LUTS).

Degree of LUTS and impact on QoL drive the management of BPH. These measures of BPH aid in quantifying such symptoms and associating them with impact on QoL. [Table 1](#tbl1){ref-type="table"} summarizes the natural history of BPH as defined by measures of BPH.

###### 

Natural history of BPH as measured by surrogate endpoints of AUASI, prostate volume, peak urinary flow, AUR, PSA, PVR, and voided volume

  Reference   No Patients   Surrogate endpoint                                                               
  ----------- ------------- -------------------- -------------------------------------------- -------------- --------------------
  [@b94]      2115          AUASI                Annual change in symptom score                              
                                                 40--79 years of age: +0.29 points per year                  
                                                 40--49 years of age: +0.13 points per year                  
                                                 60--69 years of age: +0.60 points per year                  
                                                 70--79 years of age: +0.38 points per year                  
  [@b82]      631           Prostate volume      \% Annual change in prostate volume                         
                                                 Overall: +1.6%                                              
  [@b85]      492           Peak urinary flow    \% Annual change in peak urinary flow                       
                                                 40--79 years of age: −2.14%                                 
                                                 40--49 years of age: −1.1%                                  
                                                 \>70 years of age: −6.2%                                    
                                                 Prostate volume ≤30ml: −1.7%                                
                                                 Prostate volume \>30ml: −3.0%                               
  [@b49]      2115          AUR                  Risk of AUR within 5 years                                  
                                                 40--49 years of age: 1.6%                                   
                                                 70--79 years of age: 10%                                    
  [@b105]     529           PSA                  Relative risk of prostate enlargement                       
                                                 Age                                          Baseline PSA   RR
                                                 40--49                                       ≥0.31 ng/mL    3--6-fold increase
                                                 50--59                                       ≥0.80 ng/mL    5--9-fold increase
                                                 60--69                                       ≥1.70 ng/mL    11-fold increase
  [@b93]      529           PVR                  Median annual % change PVR                                  
                                                 40--79 years of age: 2.2                                    
                                                 40--49 years of age: 1.8                                    
                                                 50--59 years of age: 4.3                                    
                                                 60--69 years of age: 2.6                                    
                                                 70--79 years of age: −2.6                                   
  [@b93]      529           Voided volume        Median annual % change voided volume                        
                                                 40--79 years of age: −2.1                                   
                                                 40--49 years of age: −1.3                                   
                                                 50--59 years of age: −1.1                                   
                                                 60--69 years of age: −4.3                                   
                                                 70--79 years of age: −4.6                                   

**Abbreviations**: AUASI, American Urological Association Symptom Index;AUR, acute urinary retention; BPH, benign prostatic hypertrophy; PSA, prostate-specific antigen; PVR, post-void residual.

BPH: Pharmacological therapy
============================

Available pharmacotherapies for BPH fall under two general categories----pha blockers and 5 alpha-reductase inhibitors. Herbal remedies, while not regulated by the Food and Drug Administration (FDA), are widely available and commonly used.

Alpha adrenergic blockers: Mechanism of action
----------------------------------------------

Alpha blockers are adrenergic receptor antagonists. In the lower urinary tract, these receptors are found in the smooth muscle of the prostate, urethra, and bladder neck ([@b17]). Adrenergic blockade results in relaxation of smooth muscle at these anatomic locations, thereby allowing a wider caliber outlet for the passage of urine.

There are two subtypes of alpha adrenergic receptor associated with prostatic smooth muscle, alpha-1 and alpha-2 ([@b14]). Antagonism of the alpha-1 subtype has shown clinical advantages in treating BPH and has thus been the focus of subsequent study. Adrenoceptor research led to the discovery, classification, and subdivision of type-1 alpha receptors into the subtypes 1~A~, 1~B~, and 1~D~ ([@b5]; [@b91]).

Phenoxybenzamine, prazosin, terazosin, doxazosin, alfuzosin, and tamsulosin are alpha blockers currently available for the treatment of BPH. Alpha blocker receptor subtype selectivity, dose, and duration of action are summarized in [Table 2](#tbl2){ref-type="table"}.

###### 

Alpha adrenergic receptor antagonists: subtype-selectivity, dosing, and duration of action

  Medication               Receptor subtype      Tablet/capsule size (mg)   Dosing schedule     Duration of action
  ------------------------ --------------------- -------------------------- ------------------- --------------------
  *Nonselective*                                                                                
  Phenoxybenzamine         α1 and α2             1 0                        10 mg bid           Long-acting
  *A1 selective*                                                                                
  Alfuzosin                α1~A~, α1~B~, α1~D~   2.5                        2.5 mg tid          Short-acting
  Alfuzosin XL             α1~A~, α1~B~, α1~D~   1 0                        10 mg qd            Long-acting
  Prazosin                 α1~A~, α1~B~, α1~D~   2                          2 mg bid            Short-acting
  Doxazosin                α1~A~, α1~B~, α1~D~   1, 2, 4, 8                 1, 2, 4, 8 mg qd    Long-acting
  Doxazosin GITS           α1~A~, α1~B~, α1~D~   4, 8                       4, 8 mg qd          Long-acting
  Terazosin                α1~A~, α1~B~, α1~D~   1, 2, 5, 10                1, 2, 5, 10 mg qd   Long-acting
  *A1 subtype-selective*                                                                        
  Tamsulosin               α1~A~, α1~D~          0.4                        0.4, 0.8            Long-acting

**Abbreviations**: bid, twice daily; GITS, gastrointestinal therapeutic system; qd, once-daily; tid, three times daily; XL, extended-release.

Phenoxybenzamine is not selective for alpha-1 versus alpha-2 adrenergic receptor. Prazosin, terazosin, doxazosin, and alfuzosin are selective for the alpha-1 receptor, but are not subtype selective ([@b37]; [@b5]; [@b91]). Tamsulosin has a relatively greater affinity for the alpha-1~A~ adrenergic receptor in comparison with the 1~B~, and no selectivity for the alpha-1~A~ versus 1~D~ receptor subtype ([@b37]; [@b34]; [@b83]; [@b91]).

Alpha adrenergic blockers: safety and efficacy
----------------------------------------------

Multiple, large, randomized, placebo-controlled trials have supported the safety and efficacy of alpha adrenergic blockers for the treatment of BPH ([@b1]; [@b41]; [@b23]; [@b60]; [@b90]; [@b2]; [@b75]; [@b31]; [@b74]; [@b92]). [Table 3](#tbl3){ref-type="table"} summarizes clinical outcomes for some of the large clinical trials of alpha blockers.

###### 

Summary of clinical trial outcomes of alpha blockers for BPH

                                                                                                            Significant changes in BPH measurements   TEAE                                          
  ---------------------------------------- ---------------- ------ ------------------------- -------------- ----------------------------------------- ----------- ------ ------------- ----- ------ ------------------------
                                                                                                                                                                                                    Dizziness (12)
                                                                                                                                                                                                    Asthenia (8)
  [@b90]                                   Terazosin        2084   12 mo                     2--10mg        AUASI                                     −7.6        −1.3   2.2           1.2   1 6    Periph. edema (4)
                                                                                                                                                                                                    Chest pain (4)
                                                                                                                                                                                                    Hernia (2)
                                                                                                                                                                                                    Dizziness (5)
  [@b65][†](#tf3-1){ref-type="table-fn"}   Alfuzosin        3901   4 to 26 weeks (mean 13)   7.5---10mg     IPSS                                      −5.4        −1     2.6           NA    6      Post. hypotens. (\<2)
                                                                                                                                                                                                    Syncope (\<2)
                                                                                                                                                                                                    Somnolence (\<2)
                                                                                                                                                                                                    Dizziness (14)
                                                                                                                                                                                                    Asthenia (5)
  [@b28]                                   Doxazosin        210    14 weeks                  1--8mg daily   IPSS                                      −9.23       NA     1.5           2.8   1 2    Periph. edema (6)
                                                                                                                                                                                                    Headache (5)
                                                                                                                                                                                                    Post. hypotens. (2)
                                                                                                                                                                                                    Dizziness(3)
  [@b25]                                   Doxazosin GITS   475    12 mo                     4--8mg         IPSS                                      −9          −1.6   3.2           NA    0      ED (1)
                                                                                                                                                                                                    Dry mouth (1)
                                                                                                                                                                                                    Prostatic disorder (1)
                                                                                                                                                                                                    Post. hypotens. (0.4)
                                                                                                                                                                                                    Abn. ejaculation (0.8)
                                                                                                                                                                                                    Dizziness (0.2)
  [@b74]                                   Tamsulosin       609    72 mo                     0.4--0.8mg     AUASI                                     −8 to −11   −2     1.01 to 2.3   1.2   15.7   Post. hypotens. (0.2)
                                                                                                                                                                                                    Syncope (0.2)

**Note**: systematic review of 11 trials, 8 of which were placebo controlled;

percentage of patients discontinuing drug due to TEAE.

**Abbreviations**: AUASI, American Urological Association Symptom Index; ED, erectile dysfunction; GITS, gastrointestinal therapeutic system; IPSS, International Prostate Symptom Score; mo, month; NA, not available; NS, not significant versus placebo; SI, symptom index;TEAE, treatment-emergent adverse events.

Phenoxybenzamine has proven efficacy in relieving symptoms of BPH, but its use is limited by severe side-effects ([@b19]; [@b18]). Approximately 30% of patients experience side-effects related to phenoxybenzamine ([@b56]). Orthostatic hypotension is the main adverse effect; however reflex tachycardia, nasal congestion, diarrhea, miosis, sedation, nausea, and vomiting are also associated ([@b103]). Interactions between phenoxybenzamine and other antihypertensive and/or vasodilatory agents can cause additive hypotensive effects. Due to the availability of alpha-1 selective agents, it is infrequently prescribed for BPH.

Prazosin, an alpha-1 selective blocker, demonstrated efficacy comparable with phenoxybenzamine without as severe a side-effect profile ([@b46]). However, a first-dose phenomenon in which patients experience faintness, dizziness, palpitation, and even syncope is associated with prazosin use. The incidence of this side-effect can be minimized with dose titration, as well as dosing before bed ([@b103]).

Terazosin has proven safety and efficacy in the treatment of BPH. Large placebo-controlled trials have demonstrated increased peak urinary flow, improved QoL and AUASI scores versus placebo ([@b57]; [@b32]; [@b90]; [@b81]) The most common adverse events are dizziness and asthenia with respective occurrence rates of 6.7% to 19.8% and 3.8% to 12.3% ([@b57]; [@b32]; [@b90]). Sixteen percent of patients on terazosin versus 11% on placebo (p \< 0.05) withdrew from the Hytrin Community Assessment Trial (n = 2084) because of treatment emergent adverse events ([@b90]). Overall, placebo-controlled trials suggest that terazosin is effective in reducing symptoms of BPH and improving QoL in patients with LUTS. However, some patients will not tolerate terazosin and may benefit from alternate pharmacotherapy.

Doxazosin has proven safety and efficacy in the treatment of BPH ([@b22]; [@b33]; [@b59]; [@b28]). It has also been shown to decrease blood pressure in hypertensive patients, while not effecting normotensive patients ([@b53]). However, the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) ([@b3]) was a large, randomized, double-blind, active-controlled trial designed to detect differences in major cardiovascular events in hypertensive patients randomized to chlorthalidone, doxazosin, amlodipine, or lisinopril. The doxazosin arm of this trial was closed early due to a significantly higher incidence of combined cardiovascular disease events, particularly congestive heart failure (CHF) ([@b3]). Prior to this study, alpha blockers were commonly an initial drug choice for treating hypertension, particularly in patients with coexisting BPH ([@b51]); however, the ALLHAT trial results demonstrated that the doxazosin group had an increased risk of CHF and was less effective than chlorthalidone at treating hypertension, resulting in multiple medication use to control blood pressure. Also, more patients discontinued doxazosin than chlorthalidone reflecting a higher incidence of adverse events.

Alfuzosin has established short term safety and efficacy. A systematic review included 11 trials and 3901 men, particularly eight trials (n = 2381) compared alfuzosin with placebo (mean duration 13 weeks, range 4 to 26 weeks) ([@b65]), Six trials reported statistically significant improvement in symptom scores in men receiving alfuzosin versus placebo. Five trials reported significant improvement in peak urinary flow over placebo. Two smaller trials (n \< 50) failed to show significant improvement in symptoms or peak urinary flow. Dizziness was the most commonly reported adverse event. Six percent of patients withdrew from the study due to treatment-emergent adverse events. Withdrawal rate was identical to placebo ([@b65]). Results of this systematic review suggest that alfuzosin is significantly efficacious in the treatment of LUTS attributable to BPH. The identical rate of withdrawal due to adverse events between alfuzosin and placebo suggest that alfuzosin is safe and well tolerated by patients.

Tamsulosin has proven long-term safety and efficacy. Narayan and colleagues ([@b74]) studied safety and efficacy in 609 patients in a four-year multicenter study. One hundred and nine patients in this trial had been on tamsulosin for six years. Significant improvement from baseline was maintained for as long as six years for total AUASI score, QoL improvement, and peak urinary flow rate. Adverse events accounted for 16% of patients discontinuing tamsulosin. Dizziness, postural hypotension, and syncope were exceedingly rare with only 0.2% of patients discontinuing tamsulosin for any one of these reasons. Less than 1% of patients discontinued tamsulosin due to abnormal ejaculation. Palacio and colleagues ([@b79]) confirmed the safety and efficacy of tamsulosin in a prospective multicenter trial including 2921 men with LUTS suggestive of BPH and twelve months of follow-up. Six and twelve month assessments demonstrated significant improvement in the IPSS score, QoL, peak urinary flow, irritative symptoms, and obstructive symptoms.

Prolonged release agents
========================

Doxazosin use for BPH is limited by its first-dose side-effect of hypotension. It requires a titration regimen that can require up to four steps ([@b25]). In response to this, doxazosin gastrointestinal therapeutic system (GITS) was developed. This controlled-release formulation has a more gradual absorption and once-daily dosing that minimizes adverse effects and may improve compliance ([@b25]). Doxazosin GITS preserves efficacy, simplifies titration and has a slightly better side-effect profile than the standard titration ([@b54]).

Alfuzosin is currently available in an immediate-, sustained-, and extended-release formulation with three times, twice-, and once-daily dosage, respectively. The extended-release preparation is equally effective as the immediate release and has not been compared with the sustained release formulation ([@b43]). Food can effect bioavailability of the extended-release formulation and patients should be advised to take the medication on a full stomach ([@b43]). Also, hepatic impairment delays elimination of alfuzosin, and therefore extended-release formulations should be avoided in patients with this condition ([@b43]). Systematic review of clinical trials for alfuzosin extended-release demonstrated a 4% discontinuation rate. Treatment emergent adverse events included dizziness (5.7%), headache (3%), and fatigue (2.7%) ([@b43]).

A new formulation of tamsulosin, oral-controlled absorption system (OCAS), is expected to be available in the near future. The current formulation is based on a controlled release formulation and is prescribed as once-daily dosing ([@b106]). Tamsulosin should be taken 30 minutes after the same meal each day to achieve steady serum levels over a 24-hour period. The new OCAS formulation will likely have altered bioavailability, onset of action and duration of action relative to the current formulation ([@b106]). However, the active agent is the same and improved efficacy should not be expected ([@b106]). Given the already convenient dosing and low incidence of adverse events with the current formulation of tamsulosin, the motivation for designing an extended-release formulation is unclear ([@b106]).

Alpha adrenergic blockers: sexual side-effects
----------------------------------------------

Alpha blockers have a low incidence of sexual side-effects. However, they can cause reversible ejaculatory dysfunction ([@b47]), in particular retrograde ejaculation. The mechanism for sexual dysfunction relates to the antagonism of the alpha receptors, located in the smooth muscle of the bladder neck, preventing closure of the bladder neck, allowing for retrograde ejaculation during climax ([@b20]).

In a review of 73 studies, sexual dysfunction associated with BPH therapy was reported ([@b20]). The risk of retrograde ejaculation with transurethral resection of the prostate (TURP) for BPH ranges from 25% to 99%. The risk is 1% with alpha blockers, but can be higher with tamsulosin ([@b20]). This may be due to alpha-1~A~ receptors in the seminal vesicles that are blocked by tamsulosin and thereby decrease the volume of ejaculate. Tamsulosin has been reported to have an incidence of ejaculatory disorder ranging from 4.5% ([@b23]) to 30% ([@b75]), however less than 1% of patients discontinued tamsulosin for this reason ([@b58]; [@b75]; [@b47]; [@b95]; [@b74]). There is concern regarding the QoL effects of ejaculatory dysfunction. Ejaculatory disorders are viewed as a mild side-effect by patients and infrequently result in discontinuation of therapy ([@b47]; [@b74]; [@b61]).

Improved overall sexual function has been reported with alpha blocker use ([@b63]; [@b47]; [@b100]). This effect may be attributed to an improved overall QoL, or possibly through a direct effect of the alpha receptor antagonism ([@b61]). Urinary symptoms associated with BPH are an independent risk factor for sexual life dissatisfaction and severe symptoms have a greater associated risk than moderate symptoms ([@b66]; [@b99]). Forty-six percent of patients seen in urologic practice report that LUTS has a negative impact on their sex lives ([@b39]).

A direct relationship between alpha blockers and improved sexual function has also been theorized. Alpha receptor antagonism in the penis causes smooth muscle relaxation resulting in relaxation of the lacunar spaces of the corpora cavernosa, thereby potentially decreasing blood flow resistance to erectile tissues and increasing erectile rigidity ([@b5]; [@b47]; [@b61]). Comparison of intracavernosal blood samples of healthy men with those of patients with sexual dysfunction suggest that somatic deregulation in sympathetic transmission, or changes of catecholamine reuptake mechanisms, may play a role in erectile dysfunction ([@b11]). This mechanism suggests another explanation regarding the efficacy of alpha blockers in erectile dysfunction ([@b44]; [@b10]).

5 alpha-reductase inhibitors: mechanism of action
-------------------------------------------------

Androgen suppression results in decreased prostate volume and improvement in LUTS ([@b69]). Dihydrotestosterone (DHT), a product of testosterone conversion by the enzyme 5 alpha-reductase, has been shown to play a role in the development of BPH ([@b27]).

Finasteride is a 5 alpha-reductase inhibitor that effectively inhibits DHT production. ([@b102]). There are two isozymes of the 5 alpha-reductase enzyme, types I and II ([@b50]). Finasteride selectively inhibits only the type II isozyme and it does not reduce DHT levels to those seen in castration ([@b98]).

Dutasteride, another 5 alpha-reductase inhibitor, differs from finasteride in that it inhibits isozymes ([@b87]). [Table 4](#tbl4){ref-type="table"} summarizes mechanism, dose, and adverse effects associated with 5 alpha-reductase inhibitors.

###### 

5 Alpha-reductase inhibitors: mechanism, dose, and associated adverse effects

  Drug Name     Mechanism                             Dose       Adverse effects
  ------------- ------------------------------------- ---------- -------------------------------------------------------------------------------------------------------------------------
  Finasteride   Inhibits type II isozyme              5mg qd     decreased libido, impotence, decreased ejaculate, ejaculation disorder, breast enlargement, breast tenderness, and rash
  Dutasteride   Inhibits type I and type II isozyme   0.5mg qd   impotence, decreased libido, gynecomastia, and ejaculation disorder

**Abbreviations**: qd, once-daily.

5 alpha-reductase inhibitors: safety and efficacy
-------------------------------------------------

The Proscar (Merck & Co., Inc., Whitehouse Station, NJ, USA) Long-Term Efficacy and Safety Study (PLESS) ([@b70]) included 3040 men with prostates greater than 50g and BPH. After four years of finasteride treatment, significantly reduced symptoms and prostate volume, increased urinary flow rate, and reduced probability of surgery and AUR were reported. There was a significant difference noted in drug-related adverse events of decreased ejaculate, ejaculation disorder, breast enlargement, breast tenderness, and rash. Decreased libido and impotence only retained significance versus placebo during the first year of the trial.

Roehrborn and colleagues ([@b87]) reported safety and efficacy results on 4325 men randomized to either dutasteride or placebo in a multicenter, double-blind trial with multiple interval assessments. Significant results at 24 months of follow-up included: serum DHT reduction by 90%, prostate volume reduction by 26%, and maximal flow rate improvement of 2.2mL/s. Risk of AUR and surgical intervention was reduced 57% and 48% versus placebo, respectively. Two year open-label extension of this trial suggests sustained and continued improvements in symptoms and flow rate ([@b88]). Significant adverse events included impotence, decreased libido, gynecomastia, and ejaculation disorder. Only gynecomastia retained significance, versus the placebo group, at 24 months. [Table 5](#tbl5){ref-type="table"} summarizes safety and efficacy outcomes for 5 alpha-reductase inhibitors.

###### 

Summary of 5 alpha-reductase inhibitor clinical trial outcomes for BPH

                                                Significant changes in BPH measurements    TEAE                     
  -------- ------------- ------ ------- ------- ------------------------------------------ ------ ----- ----- ----- --------------------------------
  [@b70]   Finasteride   3040   48 mo   5mg     AUASI[\*\*](#tf5-3){ref-type="table-fn"}   −2.6   1.9   −18   1 2   ED (8)
                                                                                                                    Decreased libido (6)
                                                                                                                    Decreased ejaculate volume (4)
                                                                                                                    Ejaculation dysfct (1)
  [@b87]   Dutasteride   2951   24 mo   0.5mg   AUASI                                      −4.5   2.2   −26   9     ED (7)
                                                                                                                    Decreased libido (4)
                                                                                                                    Gynecomastia (2)
                                                                                                                    Ejaculation dysfct (2)

**Note**:% change in volume at one year;

percentage of patients discontinuing drug due to TEAE;

"quasi-AUA score" was constructed from seven questions that were part of a larger series of questions constructed before use of AUASI.

**Abbreviations**: AUASI, American Urological Association Symptom Index; ED, erectile dysfunction; mo, month; NS, not significant versus placebo; SI, symptom index; TEAE, treatment-emergent adverse events.

Unlike alpha adrenergic blockers, the maximum efficacy of 5 alpha-reductase inhibitors is not quickly achieved. Three to six months of therapy is necessary to see maximum decrease in prostate size and resultant improvement in LUTS ([@b80]; [@b42]; [@b70]; [@b16]).

5 alpha-reductase inhibitors: QoL and sexual side-effects
---------------------------------------------------------

As part of the PLESS trial, Bruskewitz and colleagues ([@b16]) investigated the long-term effects of finasteride on QoL in men with moderate-to-severe LUTS secondary to BPH. This trial utilized a questionnaire focused on degree of bother, lifestyle interference, and sexual issues. After 4 years of follow-up, men receiving finasteride were significantly (p \< 0.01) less bothered by LUTS and had significantly less activity interference and worry about urinary function secondary to LUTS. Effects became evident after 4 months of treatment. Domains of sexual satisfaction and sexual drive were worse for the finasteride group than the placebo group, while no differences were found for the question regarding erectile difficulty.

O'Leary and colleagues ([@b77]) investigated the effect of dutasteride on BPH-specific health status. This randomized, double-blind, placebo-controlled study utilized the BPH Impact Index (BII) validated questionnaire ([@b9]) in 4325 men with LUTS due to BPH to assess quality of life. The BII is composed of four questions addressing physical discomfort, worry, degree of bother, and time away from regular activities due to urinary problems. Dutasteride versus placebo resulted in significant improvements in mean BII score after 6 months of therapy with continued improvements from six months to two years. This finding suggests that dutasteride, despite its known sexual side-effects, improves QoL in patients with BPH.

The negative impact on sexual health is greater with 5 alpha-reductase inhibitors than alpha blockers ([@b61]). The anti-androgen effects of finasteride and dutasteride should be considered when choosing a pharmacologic therapy for patients with BPH.

Combination therapy
===================

As the two classes of drugs suggest, BPH symptoms respond to both inhibition of sympathetic smooth muscle tone and gland volume reduction. The distinct mechanisms of action associated with the two drug classes suggest that combination therapy may have added benefit when compared to either of the two therapies alone.

Two trials, the Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study ([@b60]), which compared terazosin, finasteride, and combination therapy with placebo, and the Prospective European Doxazosin and Combination Therapy (PREDICT) ([@b55]) trial which compared doxazosin, finasteride, and combination therapy with placebo, failed to show any benefit of combination therapy.

The Medical Therapy of Prostate Symptoms (MTOPS) trial ([@b71]) was a multi-center, double-blind, placebo-controlled clinical trial developed to compare the efficacy of combination therapy with doxazosin and finasteride with that of either therapy alone. 3047 men were enrolled in the trial and follow-up was reported for an average of 4.5 years ([@b71]). The results demonstrated a significantly reduced risk of overall clinical progression with combination therapy. This risk was defined as "An increase above baseline of at least 4 points in the American Urological Association Symptom Score, acute urinary retention, urinary incontinence, renal insufficiency, or recurrent urinary tract infection." ([@b71]). The reduction in risk of BPH progression associated with combination therapy (66% for the combination vs placebo, p \< 0.001) was significantly greater than that associated with doxazosin (p \< 0.001) or finasteride (p \< 0.001) alone ([@b71]). The risks of AUR and the need for invasive therapy were significantly reduced by combination therapy and finasteride alone, but not by doxazosin alone. Combination therapy was superior to both doxazosin and finasteride alone ([@b71]). [Table 6](#tbl6){ref-type="table"} summarizes clinical outcomes reported by the MTOPS trial. Discontinuation rates were 27% for doxazosin, 24% for finasteride, and 18% for men who were receiving combination therapy ([@b71]). Adverse events were the most common reason for stopping treatment. The numbers of statistically significant side-effects were 5, 3, and 9 for doxazosin, finasteride, and combination therapy, respectively. Adverse events that occurred more frequently with combination therapy versus either drug alone included: abnormal ejaculation, peripheral edema, and dyspnea ([@b71]). The definition of discontinuation in the combined arm was discontinuation of both drugs, and as such more patients in the combination arm may have been on at least one drug as opposed to nothing. The intention to treat design combined with drug tolerability and definition of discontinuation could be contributing to the outcomes reported ([@b78]).

###### 

Summary of clinical trial outcomes for combination therapy for BPH

                                                                                          Significant changes in BPH measurements   TEAE                                                        
  -------- --------------------------- ------ ------- ----------------------------------- ----------------------------------------- ------ ---- ----- ---- ------------------------------------ -------------------------------------------------------------------------------------------
  [@b71]   Doxazosin and Finasteride   3047   54 mo   Finasteride 5mg; Doxazosin 4--8mg   AUASI                                     −6     NA   3.6   NA   18[†](#tf6-1){ref-type="table-fn"}   Dizziness(5) ED(5) Post.hypotension(4) Asthenia(4) Abn.ejaculation(3) Decreased libido(3)

**Note**: percentage of patients discontinuing both drugs for any reason, not only TEAE;

percentage of patients discontinuing drug due to TEAE.

**Abbreviations**: AUASI, American Urological Association Symptom Index; ED, erectile dysfunction; mo, month; NA, not available; NS, not significant versus placebo; SI, symptom index;TEAE, treatment-emergent adverse events.

Phytotherapeutics
=================

The annual prevalence of dietary supplement use in the US increased from 14.2% in 1988--1999 to 18.8% in 2002 ([@b52]). Dietary supplement use doubled for those age 65 years and older. Saw Palmetto is the second most commonly used dietary supplement in men between the ages of 45 and 64, and fourth most commonly used in men aged 65 and older ([@b52]).

Saw Palmetto
------------

Saw palmetto(*Serenoa repens*) is derived from the American dwarf palm tree berry, which naturally grows in the southeastern US ([@b36]). It has been used as a natural remedy for BPH. Although the mechanism of action has not been completely defined, the most accepted mechanism is 5 alpha-reductase inhibition ([@b36]). Saw palmetto has been investigated in large, randomized, placebo-controlled trials utilizing validated questionnaires ([@b21]; [@b40]; [@b30]; [@b29]). It has also been compared with finasteride and tamsulosin ([@b21]; [@b30]). In a recent review of the literature regarding saw palmetto, Fong and colleagues ([@b36]) concluded that this phytotherapeutic significantly improves symptom score (assessed with IPSS score) ([@b21]; [@b40]; [@b30]; [@b29]), QoL ([@b21]), and urinary flow rate ([@b21]; [@b30]). Saw palmetto has been shown to have a lower incidence of sexual dysfunction and ejaculatory disorders than both alpha blockers and 5 alpha-reductase inhibitors ([@b21]; [@b30]).

Despite previous reports, results from a recent randomized, placebo-controlled trial have called into question the efficacy of saw palmetto. Bent and colleagues ([@b12]) randomized 225 men with moderate to severe BPH to one year of treatment with saw palmetto extract or placebo. They reported no significant difference between the groups in change in AUASI score, maximal urinary flow rate, prostate size, residual volume after voiding, QoL, or PSA during the one-year study. The incidence of side-effects was similar between the two groups. [Table 7](#tbl7){ref-type="table"} summarizes the clinical outcomes reported by Bent and colleagues ([@b12]). Unlike previous studies, this trial used a placebo that was similar in appearance and smell to the pungent active agent. Furthermore, the adequacy of blinding was validated. Inadequate blinding may decrease response in a placebo group, thereby artificially increasing the response in the experimental group. Although this trial challenges current belief that saw palmetto is somewhat efficacious in treating BPH symptoms, reproduction of these results with a similar well designed trial is necessary to confirm these findings. Also, supplemental "prostate-health" preparations include various herbal extracts other than saw palmetto. The other extracts and the combined use of them may, or may not, alter efficacy of such products. We feel that patients should be made aware of the results of this trial so that they can make informed decisions regarding the use of saw palmetto for BPH symptoms.

###### 

Summary of clinical trial outcomes for combination therapy for BPH

                                                                     Significant changes in BPH measurements   TEAE                       
  ----------------- -------------- ----- ------- ------------------- ----------------------------------------- ------ ---- ---- ---- ---- ----
  Bent et al 2003   Saw Palmetto   225   12 mo   160mg twice daily   AUASI                                     NS     NS   NS   NA   NS   NS

**Note**: percentage of patients discontinuing drug due to TEAE.

**Abbreviations**:AUASI, American Urological Association Symptom Index; ED, erectile dysfunction; NS, not significant versus placebo; SI, symptom index;TEAE, treatment-emergent adverse events.

Pygeum africanum
----------------

*P. africanum* is a plant extract derived from the African plum tree that is widely used in Europe ([@b62]). A systematic review and quantitative meta-analysis was conducted to investigate the efficacy and tolerability of this phytotherapeutic in men with BPH ([@b48]). Eighteen RCTs accounting for 1562 subjects were analyzed. Mean follow-up was 64 days. Six studies involving 474 subjects compared *P. africanum* with placebo. Men were twice as likely to report an overall improvement of symptoms when taking *P. africanum* extract versus placebo. Nocturia and residual urine volume were reduced by 19% and 24%, respectively. Peak urine flow was increased by 23%. Similar to placebo (11%), 12% of patients dropped out of respective studies. Adverse events were generally mild. Gastrointestinal side-effects were the most common. Although this report is a meta-analysis, most of the included trials did not provide clinically relevant baseline and outcomes data, none were conducted in the US, no standardized validated symptom scales were used, studies were of short duration, and outcomes of acute urinary retention, renal insufficiency, or surgical intervention were not considered ([@b48]).

A randomized, double blind study comparing once and twice daily dosing of *P. africanum* investigated the safety, efficacy, and QoL outcomes in the BPH patient ([@b24]). 174 patients completed the open phase of the trial (100mg once daily) with follow-up of 12 months. IPSS score improved 46% after 12 months. Thirty-two percent of patients scored a 5 (unhappy) or a 6 (terrible) at baseline, and only 11% indicated these poor QoL scores after 12 months. After one year, 58% of patients indicated a QoL score of "mostly satisfied, pleased, or delighted." After two months, peak urinary flow significantly improved and was maintained. Prostate volume was significantly reduced by 7% after one year. Similar to the meta-analysis, gastrointestinal side-effects were the most common. Less than five percent of patients withdrew from the trial secondary to side-effects. There were no significant changes to PSA levels or sexual activity. This trial suggests safety and efficacy for once a day dosing of *P. africanum* for patients with BPH.

Less studied phytotherapies include *Urtica dioica* (stinging nettle), *Cucurbita pepo* (pumpkin seed), *opuntia* (cactus flower), *Pinus* (pine flower), *Picea* (spruce), and *Secale cereale* (rye pollen). These agents are often part of combination preparations formulated for "prostate health." Due to the lack of consistency of active agent dose and knowledge regarding pharmacokinetic information and possible drug interactions, we do not feel that there is enough evidence to recommend these products; however in our opinion it is important to be aware of the information that is available regarding herbal remedies as their use is quite common.

Differential review of agents used in BPH therapy
=================================================

In a meta-analysis, Djavan and Marberger ([@b31]) assessed whether or not alpha blockers could be distinguished based on efficacy and/or tolerability. Both placebo-controlled and comparison studies involving alfuzosin, terazosin, doxazosin, and tamsulosin were analyzed. Overall, the various alpha blockers produced similar improvements in symptom scores and urinary flow rates. Significant differences were found in side-effect profiles. Based on study withdrawal rates due to adverse events and incidence of vasodilatory adverse events, alfuzosin and tamsulosin were better tolerated than terazosin or doxazosin. Withdrawal rates for alfuzosin and tamsulosin were similar to placebo at 4% to 10%. Fourteen percent to 20% of patients taking terazosin or doxazosin withdrew from studies because they could not tolerate related adverse effects. Also, tamsulosin had less effect on blood pressure than alfuzosin or terazosin.

The safety and efficacy of alfuzosin and tamsulosin versus placebo has been studied. In a randomized, double-blind, placebo-controlled study, 625 patients were randomized to alfuzosin (10mg or 15mg), tamsulosin 0.4mg, or placebo for twelve weeks ([@b76]). Results demonstrated significant improvement in IPSS score for alfuzosin 10mg and tamsulosin versus placebo (p = 0.007, p = 0.014, respectively), while alfuzosin 15mg demonstrated a trend toward an improvement (p = 0.05). Both doses of alfuzosin and tamsulosin produced a significant increase in peak urinary flow relative to placebo (p = 0.02). Alfuzosin and tamsulosin were well tolerated. Dizziness was the most common adverse event with 4%, 6%, 7%, and 2% of patients reporting this adverse event for placebo, alfuzosin 10mg, alfuzosin 15mg, and tamsulosin, respectively. Sexual function adverse events were also low with 0%, 3%, 1%, and 8% incidence for placebo, alfuzosin 10mg, alfuzosin 15mg, and tamsulosin, respectively. Discontinuation rate (8%) was greatest with alfuzosin 15mg. This study suggests that the greatest benefit with minimized side-effects can be achieved with the use of alfuzosin 10mg or tamsulosin.

BPH treatment strategies
========================

The Triumph Project investigated treatment strategies, patterns of drug use and treatment discontinuation in men with BPH ([@b101]). Nine percent of patients newly diagnosed with BPH undergo surgery, while 45% are treated pharmacologically within the first year after diagnosis ([@b101]). Age, type of complaint, and co-morbidity are factors associated with receiving pharmacologic therapy versus watchful waiting or surgery. Alpha blockers are the most commonly prescribed first line therapy ([@b101]). Adherence rates of alpha blockers (67% at one year) are similar to 5 alpha-reductase inhibitors (73% at one year) and combination therapy (71% at one year) ([@b101]). Adherence rates do not vary within a class of medication ([@b101]). Patients with voiding symptoms (versus storage or post micturition syndromes), younger age, normal PSA, and less co-morbidity are more likely to discontinue medication ([@b101]). These treatment strategies reflect the conservative nature of BPH management, safety of alpha blockers and 5 alpha-reductase inhibitors, and risk stratification for progressive disease.

One-quarter of patients discontinue pharmacologic treatment early after starting (adherence time \<20% of total follow-up). Overall, the most common reasons for discontinuing a medication are adverse events or persistence of complaints despite therapy or resolution of complaint ([@b101]). Interestingly, adherence of once-daily dosing preparations is not significantly better than multiple dosing regimens ([@b101]).

In practice, BPH treatment is largely based on patient symptoms. Typically, we start with pharmacologic therapies and advance to minimally invasive and ultimately surgical options. Alpha blockers, particularly tamsulosin, are first line agents for BPH treatment because they are effective with limited side-effects and convenient once-daily dosing. If a patient is unable to tolerate an alpha blocker or if the medication is not efficacious we would offer a 5 alpha reductase inhibitor or a minimally invasive therapy. 5 alpha-reductase inhibitors are especially helpful in patients with large prostate glands (\>50 g) and/or symptomatic bleeding. Long-term use of 5 alpha-reductase inhibitors is somewhat controversial because of the associated increased rate of higher grade prostate cancers. As discussed earlier, the evidence for combination therapy is unclear and we do not routinely recommend it due to a 2-fold increase in side-effects and costs. Patients not desiring to take a medication are offered minimally invasive or surgical options.

Discussion
==========

Major events in the development and progression of BPH
------------------------------------------------------

Patients suffering from LUTS secondary to BPH typically experience the gradual onset of symptoms that can prompt seeking of medical treatment. Also, AUR can rarely be the presenting event. Without treatment, patients are at risk for disease progression including AUR, recurrent urinary tract infection, hydronephrosis, gross hematuria, bladder stones, bladder decompensation, overflow incontinence, renal impairment, and even renal failure can result. The impending impact these events have on QoL justifies the need for appropriate therapeutic intervention.

Critical issues in QoL
----------------------

Critical issues in QoL management with these agents relate to the subjective experience of the patient. Symptoms attributed to BPH have been shown to negatively impact QoL, therefore it is reasonable to treat these patients. However, patients with low-to-moderate symptoms may not be bothered enough to warrant medical intervention. These patients may be best served by watchful waiting because treatment side-effects may negate benefits of therapy.

Patients desiring medical treatment are at risk for adverse events. Although the risk of side-effects with the current agents is quite low, this risk can be minimized by starting with alpha adrenergic antagonists, particularly tamsulosin, and advancing to 5 alpha-reductase inhibitors.

Patients having persistent symptoms, despite alpha blocker therapy, carry the combined risk of medication side-effect and LUTS. These patients can be offered an alternate alpha blocker, trial of a 5 alpha-reductase inhibitor or a minimally invasive/surgical option.

Future directions and experimental therapy
------------------------------------------

Outside of alpha adrenergic antagonism, 5 alpha-reductase inhibition and phytotherapeutics there has not been alternate drug classes for treatment of BPH. However, new forms of monotherapy, as well as combination therapy with alpha adrenergic antagonists, are on the horizon. Further improvement of alpha adrenergic receptor subtype selectivity ([@b7]), endothelin receptor antagonists ([@b97]), phosphodiesterase inhibitors, nitric oxide, cyclic guanosine monophosphate, L-arginine, vanilloid receptor modulation, and purine receptor modulation are future therapies for the treatment of BPH ([@b4]).

Pharmacogenomics and BPH
------------------------

The efficacy and tolerability of pharmaceutical agents vary from person to person. This variability is believed to result in part from the unique interaction of a pharmaceutical agent with the genetic makeup of the individual. Pharmacogenomics is the study of this interaction. The science of pharmacogenomics is intended to produce medications individualized for one's genetic makeup thereby maximizing efficacy and tolerability.

While this line of research is still in its infancy, investigation is underway to define the association of BPH and polymorphisms of genes involved in sex hormone metabolism, growth factors, cytokine and Vitamin D receptors ([@b73]; [@b84]). Highly selective, efficacious therapies with low side-effect profiles are anticipated to result from pharmacogenomic research.

Conclusion
==========

There are a variety of safe and efficacious medical therapies available for the management of BPH and it is important for the practicing physician to have an understanding of these pharmacotherapies and their potential impact on the patient. Due to the widespread use of phytotherapies, despite adequate evidence of efficacy and safety, physicians must be aware of existing evidence for these products. Particular patient characteristics; of which age, symptom severity, co-morbidities, and sexual function are only a few, should be considered when devising a treatment plan for patients with BPH.
